ZBIO

23.8504.75%
LO

Leon Oliver Moulder

Founder, CEO & Chairman

Mr. Leon Oliver Moulder, Jr. also known as Lonnie, M.B.A., is Chairman of the Board of Zenas BioPharma, Inc since 2020 and Chief Executive Officer since August 2023 and is Founder. He serves as a Non-Executive Director at Zai Lab Limited since March 5, 2026 and was its Independent Director since January 2020 until March 5, 2026. He has been Director of Aegle Therapeutics Corporation since January 2020. He served as Director at Dianthus Therapeutics until May 22, 2025. He served as Chairman at Dianthus Therapeutics since September 2023 until July 01, 2024. Mr. Moulder serves on the Board of Directors of Aegle Therapeutics and TamuroBio. He is a Trustee of Temple University. Mr. Moulder had been Director of Helsinn Healthcare S.A., since January 13, 2020. Mr. Moulder is the Founding General Partner of Tellus BioVentures, a life sciences investment fund. He had been the Independent Chairman at Trevena, Inc. since June 2013 until November 9, 2023 and had been its Independent Director since November 2011 until December 31, 2023. Mr. Moulder Co-founded TESARO, Inc. in March 2010 and served as Chief Executive Officer and Director since March 2010 until January 2019. Mr. Moulder served as the Chief Executive Officer and President of Abraxis BioScience Inc. at Abraxis Health, Inc. from April 30, 2009 to January, 2010. Mr. Moulder served as the Chief Executive Officer and President of MGI Pharma, Inc. from May 14, 2002 to January 2008 and May 13, 2003 to January 2008, respectively. He served as an Executive Vice President of MGI Pharma, Inc., from September 1999 to January 2008 and also served as its Chief Operating Officer from May 14, 2002 to January 2008. From October 1997 to September 1999, he served as a Vice President of Business Development & Commercial Affairs and a Member of the initial management team at Eligix Inc., a developmental stage biomedical company focused on developing therapies for cancer, infectious disease and auto-immune diseases, located in Boston. He has 16 years in various sales, marketing and business development positions with Hoechst Marion Roussel (now Aventis AG) and its predecessor companies, Marion Laboratories and Marion Merrell Dow Pharmaceuticals Inc., since September 1981. Mr. Moulder's tenure at Hoechst Marion Roussel (HMR) culminated as Product Group Director of Oncology and Anti-Infective Products. He began his career as a Clinical Pharmacist. He served as a Vice Chairman of Abraxis BioScience, Inc. at Abraxis Health, Inc. from April 30, 2009 to January, 2010. He has many years of commercial management experience beginning with Marion Laboratories and ultimately advancing through various management positions at successor companies, Marion Merrel Dow and Hoechst Marion Roussel. He served as Vice Chairman of Eisai Corporation of North America following Eisai's acquisition of MGI PHARMA Inc. from January 2008 to January 2009. He served as a Director of LifeScience Alley. He serves as a Member of the Board of Visitors of the Temple University school of Pharmacy. He served as a Director of Cubist Pharmaceuticals Inc. from February 2010 to January 2015. He served as a Director of Abraxis BioScience Inc. until January 2010 and MGI Pharma Inc., from May 2003 to January 2008. He served as Director of Boston Healthcare and Biotechnology Industry Organization (BIO). He served as Director of Methylgene Inc. from 2004 to May 17, 2006. He serves on the board of the Fox Chase Cancer Center. He has a Bachelor of Science Degree in Pharmacy from Temple University and a Master of Business Administration degree from the University of Chicago Booth School of Business.

Positions